期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨肉瘤化疗耐药相关基因的研究进展 被引量：8

Gene related chemotherapy resistance of osteosarcoma
下载PDF
导出
摘要 骨肉瘤是一种常见的恶性骨肿瘤,化疗的敏感性对其预后有着重要的影响,而耐药是临床化疗中常见的失 败原因。骨肉瘤的化疗耐药牵涉到许多遗传基因学的改变,随着分子生物学技术的发展,对这些遗传基因学改变 进行敏感而特异的检测,有助于对骨肉瘤进行分子诊断、预后判断。 The sensitivity to chemotherapy is very important for the prognosis of osteosarcoma . Many genetic changes are involved in the chemotherapyresistance of osteosarcoma. With the development of molecular biology the techniques of analysis of the changes can be used as one of highly specific diagnostic tools and taken as an important prognostic indicators for designing novel therapeutic modalities.
作者 邱俊骏 施鑫 赵建宁 吴苏稼
机构地区 南京大学医学院临床学院(南京军区南京总医院)骨科
出处 《医学研究生学报》 CAS 2005年第2期164-166,共3页 Journal of Medical Postgraduates
关键词 骨肉瘤 化疗 耐药 基因 Osteosarcoma Chemotherapy Resistance Gene
分类号 R738.1 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1Lee PD, Noble-Topham SE, Bell RS et al. Quantitative analysis of multidrug resistance gene expression in human osteosarcomas[J]. Br J Cancer, 1996, 74(7): 1046-1050.
  • 2Posl M, Grahl K, Amling M et al.P-glycoprotein expression in osteosarcoma[J]. Pathologe, 1996, 17(1): 50-55.
  • 3Smith MA,Merry S,Smith JG et al. Clinically relevantcon centrations of verapamil do not enchance the sensitivity of human bone marrow. CFU. G Mtoadriamycinand VP-16[J]. Br J Cancer,1988,57(6):576-582.
  • 4Norimasa S,Tetsuro M,Tatsuto K et al. Two dyridineanalogue swith more effective ability to reverse multidrug resistance and with lower calciumchanne blocking activity than their dihydropridine counter parts[J]. Cancer Res,1990,50(5):3055-3059.
  • 5Muller F, Ferrandis GE, Cornil SI et al. Evidence for transcriptional control of human mdr1 gene expression by verapami in multidrug resistant leukemia cell[J]. Molecular Pharma Col,1995, 47(6): 51-57.
  • 6Sato W,Fukazawa N,Nakanishi O et al. Resersal of multidrug resistance by a novel quinoline derivative,MS-209[J]. Cancer Chemother Pharmacol,1995, 35(4): 271-277.
  • 7Jedlitschky G,Leier I, Buchholz U et al. ATP-dependent tran-sport of glutathiones-conjugates by the multidrug resistane-associated protein[J]. Cancer Res, 1994, 54(8): 4833-4836.
  • 8Wang J C. DNA topoisomerases [J]. Annu Rev Biochem,1996,65:635-692.
  • 9Nartey N ,Cherian MG,Banerjee D et al.Immunohisto chemical localization of metallothionein in human thyroid tumors[J]. Am J Patho1, 1987, 129(1):177-182.
  • 10Shnyder SD,Hayes AJ,Pringle J et al.P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma[J]. Br J Cancer, 1998, 78(6): 757-759.

二级参考文献8

  • 1张晓红,张福荣,籍秀娟,李占荣.KB细胞耐药株的建立及其耐药机制的探讨[J].药学学报,1994,29(4):246-251. 被引量：63
  • 2[1] Keilhauer G, Emiling F, Raschack M，et al. The use of R-VPM is superior to rasmic VPM in breaking multidrug resistance of malignant cells [J]. Proc Am Assoc Cancer Res, 1989, 30:503.
  • 3[5] Jane AP, Wishart GC, Setanoians A,et al. Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft [J]. Biochemical Pharmacology, 1994, 47: 257.
  • 4[6] Ford JM, Bruggemann EP, Pastan I ,et al. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines[J]. Cancer Res, 1990, 50: 1748.
  • 5[7] Daniela D, Mariagrazia M, Angla M ,et al. D-Verapamil downmodulaes P170-associated resistance to doxorubicin, daunorubicin and idarubicin[J]. Anticancer Drugs, 1993, 4: 173.
  • 6[8] Bissett D, Kerr DJ, Cassidy J ,et al. Phase I and Pharmacokinetic study of D-VPM and doxorubicin [J]. Br J Cancer, 1991, 64: 1168.
  • 7杨玉,龙方刚,宋炳生.R-(+)-盐酸维拉帕米的制备[J].中国医药工业杂志,1997,28(12):537-538. 被引量：4
  • 8芮建中,袁倚,盛凌树,森相秉仁,安登魁.毛细管区带电泳同时分离维拉帕米和去甲维拉帕米对映体[J].中国药学杂志,1998,33(9):553-557. 被引量：6

共引文献2

同被引文献90

引证文献8

二级引证文献23

医学研究生学报
2005年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部